Japan Leukapheresis Market (2026-2031)
The Japan Leukapheresis Market was valued at $6.07 Million in 2026 and projected to reach to $9.04 Million by 2031, representing a compound annual growth rate of 8.3%. Japan's leukapheresis market demonstrates robust growth potential driven by its aging population and elevated incidence of hematologic malignancies requiring therapeutic intervention.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan Leukapheresis Market Trends and Insights
- Japan's advanced healthcare infrastructure and aging population drive demand for therapeutic apheresis procedures, particularly in treating hematologic malignancies and autoimmune disorders.
- The country's strong regulatory framework and adoption of cell therapy technologies support market expansion throughout the forecast period. Japan's leukapheresis market benefits from increasing clinical applications and rising patient awareness of cell-based therapies.
- Japan's investment in regenerative medicine and CAR-T cell therapies has accelerated leukapheresis adoption in specialized treatment centers.
- The 8.3% compound annual growth rate reflects Japan's commitment to advancing blood cell collection technologies and expanding access to apheresis services across major metropolitan and regional healthcare facilities..
Key Market Statistics
- CAGR (2026-2031) 8.3% CAGR
- Market Size, 2026 ~USD 6.07 Million
- Forecast, 2031 ~USD 9.04 Million
- Country Japan
Japan Leukapheresis Market Overview
Market Size Trajectory :
Japan's leukapheresis market is valued at $6.07 million in 2026 and is projected to reach $9.04 million by 2031, representing a compound annual growth rate of 8.3% over the forecast period.
Aging Population Driver :
Japan's rapidly aging demographic significantly increases the prevalence of hematologic malignancies and autoimmune disorders, creating sustained demand for therapeutic apheresis procedures and leukapheresis technologies.
Advanced Healthcare Infrastructure :
Japan's sophisticated medical system, equipped with state-of-the-art facilities and high healthcare spending, supports widespread adoption of advanced leukapheresis equipment and procedures across major medical centers.
Regulatory Excellence :
Japan's stringent regulatory framework and PMDA oversight ensure high-quality standards for leukapheresis devices, fostering market confidence and enabling rapid adoption of innovative therapeutic apheresis solutions.
Japan Leukapheresis Market Dynamics
- The country's advanced healthcare infrastructure and strong regulatory environment position it as a key market for apheresis technology adoption.
- Healthcare providers increasingly recognize leukapheresis as a critical treatment modality for managing acute leukemia, chronic myeloid leukemia, and autoimmune conditions, driving procedural volume expansion. The forecast period through 2031 anticipates accelerated market expansion as Japanese hospitals and specialized treatment centers invest in next-generation leukapheresis systems.
- Growing clinical evidence supporting therapeutic apheresis, combined with improving reimbursement policies and patient awareness, will further stimulate market growth.
- Strategic partnerships between domestic healthcare providers and international apheresis manufacturers are expected to enhance market penetration and service accessibility across Japan's regions..
Related Ecosystem
Key Takeaways
- Japan's leukapheresis market is valued at $6.07 million in 2026 and is forecast to reach $9.04 million by 2031.
- Japan demonstrates an 8.3% CAGR, driven by aging demographics and increased adoption of cell therapy technologies.
- Japan's advanced healthcare system and regulatory support accelerate leukapheresis procedure adoption across treatment centers.
- Japan's investment in CAR-T and regenerative medicine therapies expands clinical applications for leukapheresis services.
Leukapheresis Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | MULTIPLE MYELOMA (Indication) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 8.9% from 2026 to 2031 |
| Largest Segment | ACUTE LYMPHOCYTIC LEUKEMIA (Indication) |
| Market Size Base Year (Billions) | ~USD 0.09 (2026) |
| Revenue Forecast (Billions) | ~USD 0.14 (2031) |
| Segments Covered | Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type |
Japan Leukapheresis Market Report Segmentation
7 segment dimensions are covered across the global market.
By Product Type
- Devices
- Disposables
- Leukapheresis Devices
- Leukapheresis Disposables
By Product Type 2024–2031
- Collection Kits & Accessories
- Filters & Membrane Consumables
- Tubing Sets & Collection Bag
By Type
- Australia
- Belgium
- Brazil
- Canada
- Centrifugal Devices
- China
- Diseased Leukopaks
- France
- Germany
- India
- Isolated Pbmcs
- Italy
- Japan
- Kingdom Of Saudi Arabia (Ksa)
- Membrane Separators
- Mexico
- Mobilized Leukopaks
- Netherlands
- New Zealand
- Non-Mobilized Leukopaks
- Poland
- Rest Of Asia Pacific
- Rest Of Europe
- Rest Of GCC Countries
- Rest Of Latin America
- Rest Of Middle East & Africa
- South Korea
- Spain
- Switzerland
- Thailand
- UK
- United Arab Emirates (UAE)
- US
By Application
- Research Applications
- Therapeutic Applications
By End User
- Academic & Research Institutes
- Blood Component Providers & Blood Centers
- Contract Research Organizations
- Hospitals & Transfusion Centers
- Pharmaceutical & Biotechnology Companies
By Indication
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Hepatocellular Carcinoma
- Multiple Myeloma
- Non-Hodgkin’S Lymphoma
- Other Indications
- Pancreatic Cancer
By Leukopak Type
- Diseased Leukopaks
- Isolated Pbmcs
- Mobilized Leukopaks
- Non-Mobilized Leukopaks
JAPAN: LEUKOPAKS MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 10.12 | 11.19 | 12.41 | 13.78 | 15.34 | 17.11 | 19.13 | 21.43 | 11.5 |
| CONTRACT RESEARCH ORGANIZATIONS | 1.06 | 1.15 | 1.25 | 1.35 | 1.47 | 1.6 | 1.75 | 1.92 | 9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 3.71 | 4.16 | 4.68 | 5.28 | 5.96 | 6.74 | 7.65 | 8.69 | 13.2 |
| TOTAL | 14.89 | 16.51 | 18.34 | 20.41 | 22.77 | 25.46 | 28.53 | 32.04 | 11.8 |
JAPAN: LEUKAPHERESIS MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 0.94 | 1.01 | 1.09 | 1.17 | 1.26 | 1.37 | 1.47 | 1.59 | 7.9 |
| BLOOD COMPONENT PROVIDERS & BLOOD CENTERS | 2.85 | 3.11 | 3.4 | 3.71 | 4.06 | 4.45 | 4.87 | 5.34 | 9.5 |
| HOSPITALS & TRANSFUSION CENTERS | 2.12 | 2.3 | 2.5 | 2.71 | 2.95 | 3.21 | 3.49 | 3.8 | 8.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 0.58 | 0.62 | 0.66 | 0.7 | 0.75 | 0.8 | 0.85 | 0.91 | 6.7 |
| TOTAL | 6.49 | 7.03 | 7.64 | 8.29 | 9.01 | 9.81 | 10.69 | 11.65 | 8.8 |
Target Audience
- Medical Device Manufacturers : Manufacturers of leukapheresis and apheresis equipment need Japan-specific market data to develop localized product strategies, establish distribution partnerships, and optimize market entry timing in this regulated healthcare environment.
- Healthcare Providers & Hospitals : Japanese hospitals and specialized treatment centers require market intelligence to justify capital investments in leukapheresis technology, benchmark against peer institutions, and plan service expansion for hematologic and autoimmune treatments.
- Pharmaceutical Companies : Pharma firms developing cell therapies and hematologic treatments need Japan market insights to understand leukapheresis adoption rates, clinical practice patterns, and patient populations requiring apheresis support therapies.
- Healthcare Investors & Consultants : Investment firms and management consultants analyzing Japan's healthcare sector require detailed market forecasts and growth drivers to identify investment opportunities and advise clients on market expansion strategies.
- Regulatory & Policy Advisors : Regulatory consultants and healthcare policy experts need Japan-specific market data to advise stakeholders on PMDA compliance, reimbursement navigation, and strategic positioning within Japan's unique healthcare regulatory framework.
Key Companies in the Japan Leukapheresis Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| MAXCYTE, INC | United States | Public Company | ExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees, |
MAXCYTE, INC
MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.
Reasons to Buy this Report
- Japan-Specific Market Sizing : Obtain precise market valuation data for Japan's leukapheresis sector with detailed 2026-2031 forecasts, enabling accurate financial planning and investment decisions tailored to this high-value Asian market.
- Demographic & Clinical Insights : Understand Japan's unique aging population dynamics and disease prevalence patterns driving leukapheresis demand, including specific incidence rates for hematologic malignancies and autoimmune disorders in the Japanese population.
- Regulatory & Reimbursement Landscape : Access comprehensive analysis of Japan's PMDA regulatory pathways, reimbursement mechanisms, and healthcare policies affecting leukapheresis market entry, pricing strategies, and competitive positioning.
- Competitive Market Dynamics : Identify key market players, distribution channels, and competitive strategies specific to Japan's leukapheresis sector, including local partnerships and market consolidation trends affecting business opportunities.
- Growth Opportunity Assessment : Evaluate high-potential segments within Japan's market including hospital adoption rates, emerging treatment centers, and geographic expansion opportunities to prioritize market entry and resource allocation strategies.
Frequently asked questions
What is the current market size of leukapheresis in Japan?
Japan's leukapheresis market is estimated at $6.07 million in 2026 and is projected to grow to $9.04 million by 2031.
What is the growth rate of Japan's leukapheresis market?
Japan's leukapheresis market is expected to grow at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2031.
What factors drive leukapheresis demand in Japan?
Japan's aging population, increased prevalence of hematologic malignancies, rising adoption of CAR-T cell therapies, and strong healthcare infrastructure drive leukapheresis market growth.
Which therapeutic applications dominate Japan's leukapheresis market?
In Japan, leukapheresis is primarily used for CAR-T cell therapy preparation, treatment of chronic myeloid leukemia, and management of autoimmune disorders.
How does Japan's leukapheresis market compare to global trends?
Japan's 8.3% CAGR is slightly below the global average of 8.9%, reflecting Japan's mature healthcare market and selective adoption of advanced apheresis technologies.
RESEARCH METHODOLOGY
This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.
A breakdown of the primary respondents is provided below:
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.
Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics
Key Stakeholders
- Apheresis device manufacturers and distributors
- Leukapheresis product manufacturers and distributors
- Leukopak manufacturers and distributors
- Pharmaceutical and biotechnology companies
- Healthcare service providers (including hospitals and transfusion centers)
- Cancer treatment centers
- Blood component providers & blood centers
- Contract research organizations (CROS)
- Academic and research institutes
- Government associations
- Market research and consulting firms
- Venture capitalists and investors
Report Objectives
- To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships
Available customizations:
With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:- Company Information
Detailed analysis and profiling of additional market players (up to 5)
- Geographic Analysis
Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries
Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries
- Competitive Landscape Assessment
Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market
Competitive leadership mapping for established players in the US
Get the Full Leukapheresis Market Report
Full forecast, segment splits, and company analysis for all Leukapheresis Market.
- Canada Leukapheresis Market
- US Leukapheresis Market
- Germany Leukapheresis Market
- UK Leukapheresis Market
- Spain Leukapheresis Market
- Italy Leukapheresis Market
- Netherlands Leukapheresis Market
- Poland Leukapheresis Market
- Switzerland Leukapheresis Market
- China Leukapheresis Market
- India Leukapheresis Market
- Australia Leukapheresis Market
- South Korea Leukapheresis Market
- New Zealand Leukapheresis Market
- Thailand Leukapheresis Market
- Brazil Leukapheresis Market
- Mexico Leukapheresis Market
- Belgium Leukapheresis Market
- France Leukapheresis Market
- Rest Of Europe Leukapheresis Market
- Rest Of Asia Pacific Leukapheresis Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report